Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Ionis Pharmaceuticals (NASDAQ:IONS), currently valued at $6.69 billion, has seen its stock surge over 30% in the past six months. Chief Executive Officer Brett P. Monia sold 1,160 shares of common stock on July 11, 2025, for a total of $48,416. The shares were sold at weighted average price of $41.7381, in multiple transactions at prices ranging from $41.67 to $41.79.
Following the transaction, Monia directly owns 179,820 shares of Ionis Pharmaceuticals.
The sale was executed under a Rule 10b5-1 trading plan adopted on August 13, 2024. Investors should note that Ionis is scheduled to report its next earnings on July 31, 2025, which could provide crucial insights into the company’s performance.
In other recent news, Ionis Pharmaceuticals has seen several key developments. Barclays (LON:BARC) upgraded Ionis Pharmaceuticals from Equalweight to Overweight, raising the price target to $57.00, citing positive expectations for the upcoming Phase 3 trial results of Tryngolza in treating severe hypertriglyceridemia. Meanwhile, H.C. Wainwright maintained its buy rating with a $50.00 price target following promising clinical trial results for salanersen, a treatment for spinal muscular atrophy (SMA). Ionis announced that its partner Biogen (NASDAQ:BIIB) reported encouraging interim results from a Phase 1 study of salanersen, highlighting significant reductions in neurofilament light chain levels and improvements in motor function among participants.
Additionally, Ionis Pharmaceuticals initiated a Phase 3 trial of ION582 for Angelman syndrome, aiming to evaluate improvements in expressive communication and other secondary endpoints. In a leadership update, Ionis announced that Chief Development Officer Richard Geary will retire in January 2026, with Holly Kordasiewicz set to succeed him. Kordasiewicz, who has been with the company since 2011, currently oversees the neurology program. These recent developments reflect Ionis Pharmaceuticals’ ongoing efforts in advancing its clinical pipeline and strategic leadership transitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.